









Markets
/
Stocks
/
nasdaq-telo
/

Telomir Pharmaceuticals Inc

TELO

1.150USD

+0.030+2.68%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

38.91MMarket Cap

LossP/E TTM



Telomir Pharmaceuticals Inc

1.150

+0.030+2.68%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Telomir Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

Telomir Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 128 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 15.50.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Telomir Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

128 / 159

Overall Ranking

487 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Telomir Pharmaceuticals Inc Highlights

StrengthsRisks

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -3.14, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 2.37M shares, decreasing 25.79% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.14M shares of this stock.

Analyst Rating

Based on 0 analysts

Current Rating

15.500

Target Price

+1283.93%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Telomir Pharmaceuticals Inc is 6.88, ranking 136 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.88

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.61

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Telomir Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Telomir Pharmaceuticals Inc is 5.76, ranking 142 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -3.14, which is -33.00% below the recent high of -2.10 and -692.30% above the recent low of -24.86.

Score

Industry at a Glance

Previous score

5.76

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 128/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for Telomir Pharmaceuticals Inc. The Pharmaceuticals industry's average is 7.85. The average price target is 15.50, with a high of 15.50 and a low of 15.50.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Telomir Pharmaceuticals Inc is 5.36, ranking 141 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.37 and the support level at 1.00, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.31

Change

0.05

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.034

Sell

RSI(14)

36.287

Neutral

STOCH(KDJ)(9,3,3)

26.454

Neutral

ATR(14)

0.069

High Vlolatility

CCI(14)

-86.272

Neutral

Williams %R

73.333

Sell

TRIX(12,20)

-0.657

Sell

StochRSI(14)

56.186

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.166

Sell

MA10

1.209

Sell

MA20

1.278

Sell

MA50

1.344

Sell

MA100

1.408

Sell

MA200

1.621

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Telomir Pharmaceuticals Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 6.89%, representing a quarter-over-quarter decrease of 19.09%. The largest institutional shareholder is The Vanguard, holding a total of 1.14M shares, representing 3.31% of shares outstanding, with 21.74% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Bay Shore Trust

6.73M

-1.30%

Mira Pharmaceuticals, Inc

3.52M

McNulty (Brian Patrick)

1.88M

-2.54%

DeJoria (John Paul)

1.77M

The Vanguard Group, Inc.

Star Investors

1.10M

-1.47%

Aminov (Erez)

1.01M

+3288.20%

Eagle (Craig)

487.81K

BlackRock Institutional Trust Company, N.A.

287.80K

-19.39%

Millennium Management LLC

222.40K

-10.21%

Geode Capital Management, L.L.C.

196.03K

-0.43%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Telomir Pharmaceuticals Inc. The Pharmaceuticals industry's average is 5.18. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.